{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-312560","form_type":"8-K","ticker":"ARTV","cik":"0001817241","company_name":"Artiva Biotherapeutics, Inc.","filed_at":"2026-07-22T21:15:36+00:00","discovered_at":"2026-07-22T21:18:00.289063+00:00","generated_at":"2026-07-22T21:18:09.258539+00:00","sec_items":["8.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"Artiva Biotherapeutics sets 2026 annual meeting for Sept 8; stockholder proposal deadline Aug 1","bullets":["Annual meeting scheduled for September 8, 2026.","Stockholder proposals and nominations due by close of business on August 1, 2026.","Deadline applies to both business brought before meeting and director nominations.","Rule 14a-8 proposals for proxy inclusion also due by August 1, 2026.","Notices must be sent to Artiva's principal executive offices in San Diego."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-312560","json":"https://secwatch.observer/filing/0001193125-26-312560.json","markdown":"https://secwatch.observer/filing/0001193125-26-312560.md","text":"https://secwatch.observer/filing/0001193125-26-312560.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526312560/0001193125-26-312560-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526312560/artv-20260722.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-22T21:18:09.258539+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}